AKBA Projected Dividend Yield
Akebia Therapeutics Inc ( NASDAQ : AKBA )Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. Co. is focused on developing and commercializing therapeutics. Co.'s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the U.S. for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). 21 YEAR PERFORMANCE RESULTS |
AKBA Dividend History Detail AKBA Dividend News AKBA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |